Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
Proteinuria has been described as a major on-target adverse event of lenvatinib, although its long-term impact on renal function and clinical outcomes remains unclear. We conducted a retrospective observational study to assess renal function and prognosis in patients with radioiodine-refractory diff...
Saved in:
Main Authors: | Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi |
---|---|
Format: | Article |
Language: | English |
Published: |
The Japan Endocrine Society
2024-04-01
|
Series: | Endocrine Journal |
Subjects: | |
Online Access: | https://www.jstage.jst.go.jp/article/endocrj/71/4/71_EJ23-0378/_html/-char/en |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01) -
Approach to investigation and management of proteinuria in pregnancy
by: Isabela Bertoni, et al.
Published: (2025-01-01) -
Proteinuria and the risk of Incident atrial fibrillation according to glycemic stages: a nationwide population-based cohort study
by: Muhan Yeo, et al.
Published: (2025-01-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)